Cargando…
Single Layer Extended Release Two-in-One Guaifenesin Matrix Tablet: Formulation Method, Optimization, Release Kinetics Evaluation and Its Comparison with Mucinex(®) Using Box-Behnken Design
Guaifenesin, a highly water-soluble active (50 mg/mL), classified as a BCS class I drug. Owing to its poor flowability and compressibility, formulating tablets especially high-dose one, may be a challenge. Direct compression may not be feasible. Bilayer tablet technology applied to Mucinex®, endures...
Autores principales: | Morovati, Amirhosein, Ghaffari, Alireza, Erfani jabarian, Lale, Mehramizi, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843298/ https://www.ncbi.nlm.nih.gov/pubmed/29552045 |
Ejemplares similares
-
Formulation Optimization and Assessment of Dexamethasone Orally Disintegrating Tablets Using Box-Behnken Design
por: Soroush, Hadis, et al.
Publicado: (2018) -
Daily use of guaifenesin (Mucinex) in a patient with chronic bronchitis and pathologic mucus hypersecretion: A case report
por: Storms, William W., et al.
Publicado: (2018) -
Improved quality of life associated with long-term daily use of guaifenesin (Mucinex(®)) in a patient with chronic rhinosinusitis: a case report
por: Singer, Ethan, et al.
Publicado: (2018) -
Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
por: Oliveira, Paulo Renato, et al.
Publicado: (2013) -
Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)